Accelerating new rare disease therapies through collaboration agreement Cambridge, MA, USA & Rostock/Berlin, GERMANY,13 November 2019 – CENTOGENE (Nasdaq: CNTG),commercial-stage company …
News
Centogene AG Rings The Nasdaq Stock Market Closing Bell in Celebration of its IPO
…
CENTOGENE Announces Proposed Initial Public Offering of Common Shares
October 28, 2019 at 8:53 AM EDT CAMBRIDGE, Mass. and ROSTOCK, Germany, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Centogene B.V. (“Centogene” or the “Company”), a commercial-stage company focused on rare …
Neurimmune and TVM Capital Life Science Announce the Initiation of AL-S Pharma’s Phase 1 Study of AP-101 for the Treatment of ALS
Schlieren, Switzerland – October 16, 2019 – AL-S Pharma AG, a biotech company jointly founded and financed by Neurimmune and TVM Capital Life Science, announced today enrollment of the first patient …
Lilly’s REYVOW™ (lasmiditan), The First and Only Medicine in a New Class of Acute Treatment for Migraine, Receives FDA Approval
The approval of REYVOW is significant because it represents the first new class of acute migraine treatment approved by the FDA in more than two decades INDIANAPOLIS, Oct. 11, 2019 /PRNewswire/ -- …
Emovi Announces Results of Clinical Trial to Manage Knee Osteoarthritis with KneeKGTM
Results demonstrates that use of KneeKG in patients with osteoarthritis reduces pain, improves patient quality of life, and may reduce need for unnecessary surgery. Montreal, Quebec (October 1st, …